Overview

An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratu

Status:
RECRUITING

Trial end date:
2029-01-05

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of the alternating D-PAD/D-CVD induction regimen followed by D-CVD consolidation regimen and maintenance with daratumumab monotherapy, in terms of PFS, in the first-line setting of pPCL.

Phase:

PHASE2

Details

Lead Sponsor:

Hellenic Society of Hematology

Treatments:

daratumumab